Corcept Therapeutics Incorporated (CORT)
NASDAQ
Market Cap
$6.25B
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
619 of 966
Rank in Industry
341 of 554
Largest Insider Buys in Sector
CORT Stock Price History Chart
CORT Stock Performance
About Corcept Therapeutics Incorporated
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with advanced ovarian tumors, as well as for the treatment of cortisol excess. The company is also developing selective cortisol modulator to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain and other disorders; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated was incorporated in 1998 and is headquartered in Menlo Park, California.
Insider Activity of Corcept Therapeutics Incorporated
Over the last 12 months, insiders at Corcept Therapeutics Incorporated have bought $0 and sold $9.63M worth of Corcept Therapeutics Incorporated stock.
On average, over the past 5 years, insiders at Corcept Therapeutics Incorporated have bought $2.34M and sold $8.44M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 150,000 shares for transaction amount of $3.23M was made by BAKER G LEONARD JR (director) on 2021‑06‑11.
List of Insider Buy and Sell Transactions, Corcept Therapeutics Incorporated
| 2024-11-22 | Sale | Chief Business Officer | 2,609 0.0024% | $56.20 | $146,626 | +2.90% | ||
| 2024-11-22 | Sale | See Remarks | 1,411 0.0013% | $56.72 | $80,032 | +2.90% | ||
| 2024-11-11 | Sale | director | 2,200 0.0021% | $59.88 | $131,736 | -0.81% | ||
| 2024-11-04 | Sale | Chief Development Officer | 3,394 0.0032% | $48.97 | $166,204 | +17.02% | ||
| 2024-10-01 | Sale | Chief Business Officer | 11,000 0.0113% | $46.28 | $509,080 | +8.97% | ||
| 2024-10-01 | Sale | Chief Development Officer | 10,000 0.0102% | $46.28 | $462,800 | +8.97% | ||
| 2024-09-03 | Sale | Chief Development Officer | 10,000 0.0099% | $35.30 | $353,000 | +37.27% | ||
| 2024-08-26 | Sale | Chief Business Officer | 3,101 0.003% | $35.71 | $110,737 | +33.57% | ||
| 2024-08-01 | Sale | Chief Development Officer | 10,000 0.0098% | $38.67 | $386,700 | +19.57% | ||
| 2024-08-01 | Sale | director | 150 0.0001% | $38.50 | $5,775 | +19.57% | ||
| 2024-07-01 | Sale | Chief Business Officer | 11,000 0.0109% | $32.49 | $357,390 | 0.00% | ||
| 2024-07-01 | Sale | See Remarks | 5,000 0.0049% | $32.49 | $162,452 | 0.00% | ||
| 2024-07-01 | Sale | Chief Development Officer | 10,000 0.0099% | $32.49 | $324,900 | 0.00% | ||
| 2024-07-01 | Sale | director | 2,200 0.0022% | $32.81 | $72,182 | 0.00% | ||
| 2024-06-03 | Sale | See Remarks | 5,000 0.0046% | $30.18 | $150,916 | +21.21% | ||
| 2024-06-03 | Sale | Chief Development Officer | 10,000 0.0098% | $32.00 | $320,000 | +21.21% | ||
| 2024-06-03 | Sale | director | 2,200 0.002% | $30.21 | $66,462 | +21.21% | ||
| 2024-05-28 | Sale | Chief Business Officer | 11,000 0.0102% | $30.39 | $334,294 | +12.97% | ||
| 2024-05-28 | Sale | Chief Development Officer | 30,000 0.0292% | $32.00 | $960,000 | +12.97% | ||
| 2024-05-13 | Sale | See Remarks | 50,000 0.0488% | $28.00 | $1.4M | +27.24% |
Insider Historical Profitability
18.52%
| Maduck Sean | See Remarks | 85222 0.0813% | $59.68 | 0 | 26 | |
| Robb Gary Charles | Chief Business Officer | 20163 0.0192% | $59.68 | 1 | 26 | +72.23% |
| Lyon Joseph Douglas | See Remarks | 8494 0.0081% | $59.68 | 0 | 22 | |
| Guyer William | Chief Development Officer | 5796 0.0055% | $59.68 | 0 | 8 | |
| Swisher Daniel N JR | director | 0 0% | $59.68 | 0 | 23 | |
| ALTA BIOPHARMA PARTNERS II LP | 10 percent owner | 5484063 5.2341% | $59.68 | 2 | 0 | +16.86% |
| PENHOET EDWARD | 5484063 5.2341% | $59.68 | 1 | 0 | +78.79% | |
| SUTTER HILL VENTURES | 10 percent owner | 5217464 4.9797% | $59.68 | 6 | 0 | +59.94% |
| MARDUEL ALIX | 10 percent owner | 5043299 4.8135% | $59.68 | 3 | 0 | +59.16% |
| GAITHER JAMES C | 10 percent owner | 4338742 4.141% | $59.68 | 5 | 0 | +56.16% |
| Speiser Michael L | 10 percent owner | 4338742 4.141% | $59.68 | 1 | 0 | +13% |
| BAKER G LEONARD JR | director | 3308303 3.1575% | $59.68 | 40 | 5 | +21.66% |
| BELANOFF JOSEPH K | Chief Executive Officer | 2538218 2.4225% | $59.68 | 0 | 101 | |
| SCHATZBERG ALAN F | director, 10 percent owner | 2438749 2.3276% | $59.68 | 1 | 1 | +197.78% |
| SINGER DAVID B | director | 731667 0.6983% | $59.68 | 0 | 2 | |
| YOUNGER WILLIAM H JR | 10 percent owner | 575066 0.5489% | $59.68 | 6 | 0 | +59.94% |
| COXE TENCH | 10 percent owner | 360048 0.3436% | $59.68 | 6 | 0 | +59.94% |
| ANDERSON DAVID L | 10 percent owner | 289747 0.2765% | $59.68 | 6 | 0 | +59.94% |
| COOK JOSEPH C JR | director | 241521 0.2305% | $59.68 | 18 | 1 | +61.71% |
| ANDERSSON ALLEN | director | 209694 0.2001% | $59.68 | 46 | 8 | <0.0001% |
| Paperboy Ventures, LLC | director | 209694 0.2001% | $59.68 | 46 | 6 | <0.0001% |
| Longitude Venture Partners L.P. | 10 percent owner | 180103 0.1719% | $59.68 | 3 | 16 | +27.2% |
| BRADBURY DANIEL | director | 177925 0.1698% | $59.68 | 4 | 12 | +44.97% |
| BIRD JEFFREY W | 10 percent owner | 126252 0.1205% | $59.68 | 6 | 0 | +59.94% |
| WHITE JAMES N | 10 percent owner | 121117 0.1156% | $59.68 | 6 | 0 | +59.94% |
| ENRIGHT PATRICK G | director | 114675 0.1094% | $59.68 | 3 | 23 | +27.2% |
| SANDS GREGORY P | 10 percent owner | 109913 0.1049% | $59.68 | 7 | 1 | +49.02% |
| Hunt Hazel | Chief Scientific Officer | 73146 0.0698% | $59.68 | 0 | 1 | |
| Harper James A | director | 57900 0.0553% | $59.68 | 6 | 0 | +81.34% |
| SWEET DAVID E | 10 percent owner | 18480 0.0176% | $59.68 | 6 | 0 | +59.94% |
| SHEEHAN ANDREW T | 10 percent owner | 18325 0.0175% | $59.68 | 4 | 0 | +17.87% |
| MAHONEY DAVID L | director | 11297 0.0108% | $59.68 | 12 | 9 | +42.33% |
| TURNER JOSEPH L | director | 10000 0.0095% | $59.68 | 2 | 0 | <0.0001% |
| GALA RENEE D | director | 10000 0.0095% | $59.68 | 2 | 0 | <0.0001% |
| KURLAND FRED | Chief Financial Officer | 7500 0.0072% | $59.68 | 2 | 0 | +11.49% |
| FISHMAN ROBERT S | Chief Medical Officer | 0 0% | $59.68 | 0 | 12 | |
| WILSON JAMES N | director | 0 0% | $59.68 | 4 | 28 | +50.46% |
| ROE ROBERT L | President and Secretary | 0 0% | $59.68 | 0 | 73 | |
| Lo Steven | VP Commercial Operations | 0 0% | $59.68 | 0 | 4 |
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
| BlackRock | $423.85M | 16.16 | 16.83M | +2.55% | +$10.54M | 0.01 | |
| The Vanguard Group | $240.96M | 9.19 | 9.57M | +0.3% | +$711,617.50 | <0.01 | |
| Ingalls Snyder Llc | $209.16M | 7.98 | 8.3M | -0.58% | -$1.23M | 9.78 | |
| Renaissance Technologies | $179.31M | 6.84 | 7.12M | +5.84% | +$9.89M | 0.29 | |
| Parallel Advisors, LLC | $96.12M | 3.67 | 3.82M | +1.26% | +$1.19M | 2.62 | |
| State Street | $90.07M | 3.43 | 3.58M | +5.55% | +$4.74M | <0.01 | |
| Dimensional Fund Advisors | $64.68M | 2.47 | 2.57M | +11.14% | +$6.48M | 0.02 | |
| Novo Holdings A/S | $60.74M | 2.32 | 2.41M | 0% | +$0 | 4.24 | |
| Geode Capital Management | $54.36M | 2.07 | 2.16M | +5.48% | +$2.83M | 0.01 | |
| First Trust | $46.32M | 1.77 | 1.84M | +1,150.82% | +$42.62M | 0.05 | |
| Boston Trust Walden Corp | $46.23M | 1.76 | 1.84M | -0.64% | -$298,022.89 | 0.33 | |
| Arrowstreet Capital, Limited Partnership | $42.49M | 1.62 | 1.69M | +53.18% | +$14.75M | 0.04 | |
| Morgan Stanley | $38.11M | 1.45 | 1.51M | +16.74% | +$5.46M | <0.01 | |
| Man Group Plc | $37.76M | 1.44 | 1.5M | +81.44% | +$16.95M | 0.09 | |
| D. E. Shaw & Co. | $28.54M | 1.09 | 1.13M | -31.69% | -$13.24M | 0.03 | |
| Voloridge Investment Management, LLC | $26.03M | 0.99 | 1.03M | +88.79% | +$12.24M | 0.1 | |
| Northern Trust | $24.27M | 0.93 | 963,443 | -11.73% | -$3.23M | <0.01 | |
| Charles Schwab | $23.51M | 0.9 | 933,461 | +3.67% | +$831,698.21 | 0.01 | |
| Fidelity Investments | $21.47M | 0.82 | 852,345 | +19.81% | +$3.55M | <0.01 | |
| Two Sigma | $20.62M | 0.79 | 818,475 | +71.39% | +$8.59M | 0.03 | |
| Invesco | $19.4M | 0.74 | 770,280 | +13.79% | +$2.35M | <0.01 | |
| Two Sigma Advisers LP | $19.15M | 0.73 | 760,200 | +41.72% | +$5.64M | 0.03 | |
| Jupiter Fund Management | $18.75M | 0.72 | 744,469 | +1,148.98% | +$17.25M | 0.05 | |
| Jacobs Levy Equity Management | $18.43M | 0.7 | 731,468 | New | +$18.43M | 0.07 | |
| BNY Mellon | $18.24M | 0.7 | 724,022 | -6.31% | -$1.23M | <0.01 | |
| Cerity Partners | $17.02M | 0.65 | 675,843 | +812.48% | +$15.16M | 0.05 | |
| Bank of America | $16.96M | 0.65 | 673,354 | +134.29% | +$9.72M | <0.01 | |
| ClearBridge Investments | $14.67M | 0.56 | 582,355 | New | +$14.67M | 0.01 | |
| Millennium Management LLC | $13.93M | 0.53 | 553,007 | -19.86% | -$3.45M | 0.01 | |
| Connor Clark & Lunn Investment Management Ltd | $13.66M | 0.52 | 542,178 | +50.1% | +$4.56M | 0.03 | |
| Goldman Sachs | $10.95M | 0.42 | 434,722 | -18.4% | -$2.47M | <0.01 | |
| Burney Wealth Management | $10.87M | 0.42 | 431,638 | +2.96% | +$312,406.11 | 0.46 | |
| Cubist Systematic Strategies | $8.85M | 0.34 | 351,374 | +51.01% | +$2.99M | 0.08 | |
| ROYCE & ASSOCIATES INC | $8.47M | 0.32 | 336,272 | +0.06% | +$4,962.43 | 0.08 | |
| Cambridge Investment Research Advisors Inc | $8.17M | 0.31 | 324,271 | +2,922.66% | +$7.9M | 0.03 | |
| Ameriprise Financial | $7.38M | 0.28 | 292,900 | +6.57% | +$455,151.96 | <0.01 | |
| S&T Bank | $7.32M | 0.28 | 290,487 | -9.46% | -$764,452.91 | 1.4 | |
| Barclays | $6.93M | 0.26 | 275,244 | +51.61% | +$2.36M | <0.01 | |
| Janus Henderson | $6.68M | 0.26 | 265,049 | +482.55% | +$5.53M | <0.01 | |
| Citadel Advisors LLC | $6.66M | 0.25 | 264,309 | -40.2% | -$4.48M | <0.01 | |
| AQR Capital | $6.51M | 0.25 | 258,408 | +182.62% | +$4.21M | 0.01 | |
| Legal & General | $6.36M | 0.24 | 252,443 | +0.39% | +$24,686.20 | <0.01 | |
| Franklin Templeton Investments | $6.18M | 0.24 | 245,462 | +7.86% | +$450,321.65 | <0.01 | |
| Acadian Asset Management | $5.94M | 0.23 | 236,199 | -13.73% | -$946,187.14 | 0.02 | |
| Nuveen | $5.52M | 0.21 | 219,037 | -16.84% | -$1.12M | <0.01 | |
| Engineers Gate Manager Lp | $5.21M | 0.2 | 206,751 | +1,744.34% | +$4.93M | 0.12 | |
| RhumbLine Advisers | $5.21M | 0.2 | 206,744 | -2.61% | -$139,778.66 | 0.01 | |
| Allianz Asset Management Gmbh | $5.06M | 0.19 | 200,893 | +311.51% | +$3.83M | 0.01 | |
| AllianceBernstein | $5.02M | 0.19 | 199,354 | -18.46% | -$1.14M | <0.01 | |
| JPMorgan Chase | $4.88M | 0.19 | 193,571 | -3.01% | -$151,467.49 | <0.0001 |
Investing Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.